Innovative Compounding Pharmacy (Innovative Intrathecal Solutions, Inc.), Murrieta, CA
Is Innovative Compounding Pharmacy (Innovative Intrathecal Solutions, Inc.) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Innovative Compounding Pharmacy (Innovative Intrathecal Solutions, Inc.) hold a California pharmacy license?
The California State Board of Pharmacy lists license PHY 49935 for Innovative Compounding Pharmacy, Murrieta, status Active, as of Nov 6, 2026.
Has Innovative Compounding Pharmacy (Innovative Intrathecal Solutions, Inc.) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Apr 4, 2022), 1 state referral letter (Apr 4, 2022) and 1 FMD-145 letter (Apr 4, 2022) for Innovative Compounding Pharmacy (Innovative Intrathecal Solutions, Inc.). State board actions: no California State Board of Pharmacy action on license PHY 49935 or under this exact name and city was found in the board’s posted disciplinary decisions on facility licenses (actions dated Jan 5, 2005 to Oct 28, 2026) on Nov 6, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Innovative Intrathecal Solutions, Inc.; Innovative Compounding Pharmacy
- Location
- Murrieta, CA
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Apr 4, 2022
- FDA Data Dashboard inspections
- 2 inspections: 1 OAI, 1 VAI; 3 published Form 483s
- Form 483 text on this page
- 3 Form 483s, 17 observations
- State board records
- License found: PHY 49935, Active
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Innovative Intrathecal Solutions, Inc. (dba Innovative Compounding Pharmacy), a 503A facility, with 5 dated actions.
| Document | |||
|---|---|---|---|
| Apr 4, 2022 | State referral letter | State Referral Letter Issued 04/04/2022 | Not linked by FDA |
| Apr 4, 2022 | Warning letter close-out | Warning Letter Close Out Issued 04/04/2022 | Not linked by FDA |
| Apr 4, 2022 | FMD-145 letter | FMD-145 Letter Issued 04/04/2022 | Not linked by FDA |
| Oct 26, 2021 | Form 483 | 483 Issued 10/26/2021 | FDA copy (archived) |
| Feb 20, 2020 | Form 483 | 483 Issued 02/20/2020 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Innovative Intrathecal Solutions, Inc., Murrieta, CA (FEI number 3013556857), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Oct 26, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3013556857 | 1155775 |
| Feb 20, 2020 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3013556857 | 1119189 |
Form 483s FDA has published for this site
- Oct 26, 2021: Form 483 to Innovative Intrathecal Solutions, Inc., published Nov 19, 2021. fda.gov
- Mar 2, 2020: Form 483 to Innovative Intrathecal Solutions, Inc., published Mar 9, 2020. fda.gov
- Dec 18, 2017: Form 483 to Innovative Intrathecal Solutions, Inc., published Mar 18, 2020. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 17 numbered observations in all, across 3 inspections ending Dec 18, 2017 to Oct 26, 2021. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Oct 26, 2021: 1 observation
- Firm on the cover
- Innovative Intrathecal Solutions, Inc. dba Innovative Compounding Pharmacy, 41538 Eastman Dr Ste A, Murrieta, CA 92562- 8007
- FEI number
- 3013556857
- Establishment type on the cover
- Producer of Non-Sterile Drugs
- FDA district office on the cover
- 1
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
You produced hazardous drugs without providing adequate containment, segregation and cleaning of personnel to prevent cross- contamination.
Specifically,
On 12-0ct-2021, during the cleaning process before and after compounding of hazardous non-sterile drug product (Progesterone Phytobase, Lot 10192021), we observed that the technician's personal protective equipment (PPE), particularly the sleeve of the gown, was constantly in direct contact and rubbing on the surface of the work bench located in the NIOSH hazard compounding room. Since the same PPE gown is used throughout the day and the firm may compound different types of hazardous drug products, there is a risk of potential carryover of one hazardous non-sterile drug product to the next drug product. Furthermore, procedure 05-A- llA.0l, "Competency Assessment: Hazardous Drug Hand Hygiene and Garbing", Date 3/20, does not require gowning or sleeves be changed between the compounding of different drug products.
Inspection Feb 10, 2020 to Feb 20, 2020: 10 observations
- Firm on the cover
- Innovative lntrathecal Solutions, Inc. dba, 41538 Eastman Dr Ste A, ANd ZIP CODE Murrieta, CA 92562-8007
- FEI number
- 3013556857
- Establishment type on the cover
- Producer of Sterile and Non-sterile Drugs
- FDA district office on the cover
- 19701 Fairchild Irvine. CA 92612-2445
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
The ISO S classified aseptic processing areas had difficult to clean and visibly dirty equipment or surface.
Specifically,
From 02/10 - 14/2020, within the ISO 7 classified clean room, the <Redacted B4> ISO 5 classified laminar airflow hoods used for sterile drug processing contained visible discoloration and yellow stains on the glass, yellpw-brown stains al the junction of the glass to the work surface, a solid brown stain at the HEPA filter in hood <Redacted B4> spotty brown stains on the HEPA filter in hood and brown spotty stains at the grating in front of the HEPA filter in hood The glass to work surface junctions contain difficult to clean gaps. In addition, there are porous spaces on the surfaces beneath the ISO 5 hoods, dark brown stained shelving adjacent to the hoods, peeling paint in the drawers and brown residue on the drawer hinges adjacent to the hoods, and cardboard material in the shelves and cabinets within the clean room. <Redacted B4> of Atropine eye drops lot 02122020@8 occurred on 02/12/2020 in lSO 5 hood <Redacted B4> in the presence of these visibly dirty surfaces and equipment. Drugs produced in these hoods in the cleanroom include but are not limited to: ...
Observation 2
You had inadequate HEPA filter coverage and air/low over the area to which sterile product was exposed.
Specifically,
On 11/25/2019, during the ISO Classified Room and Laminar Airflow Hood recertifications, lSO 5 Hood Serial
Number <Redacted B4> had a 0. 10% leak result requiring a 1/2" x 4" patch and ISO 5 Hood Serial Number <Redacted B4> had two leaks greater than 0.04% leak results requiring two patches sized 1/2'' x 2" and l" x 2". Drugs produced within these ISO 5 hoods prior to the discovery of the leak and after the previous passing leak test on July 9, 2019, include but are not limited to:
• Hydromorphone 1 mg+ Clonidine 100 mcg/ mL intrathecal lnjection lot 11222019@41
• Hydromorphone 20 mg+ Bup 800mcg / mL intrathecal Injection lot 11222019@40
• Morphine Sul 3 mg/mL Intrathecal intrathecal Injection lot 11222019@37
• Edetate disodium Ophthalmic 3% drops lot LI 222019@27
• Fentanyl 4mg + Bup IO mg /mL intrathecal lnjection lot 112220 l 9@17
• Baclofen 250 mcg/mL intrathecal Injection lot 11222019@2 1
• Methylprednisolone 80 mg/mL injection lot 112020 19@60
• Sufentani I 5000 mcg + Bup 10 mg + Clonidine 500 mcg / mL injection lot 11 202019@27 ...
Observation 3
Your firm failed to conduct adequate cleaning and disinfection in aseptic processing areas.
Specifically,
4 I. On 02/10/2020, the <Redacted B4> ISO 5 laminar air flow hoods were in the off position, and stated to be off throughout the weekend. No additional cleaning, sanitation, or environmental sampling was conducted following the shutdown of the ISO 5 hoods. Drugs produced after the shutdown of the hoods include but are not limited to:
- Morphine Sul 2 5mg /ml Inj lot 02112 020@5 1 - Hydropmorphone 25 mg & Bup 2mg/ml In j lot 02112020@61 : Baclofen 2 000 mcg/ml Inj lot 0213202 0@3 _B ac lofen 4000 mcg/ml PFNS sol inj lot 021 0202 0@26RCP 02/20/2020
Observation 4
Materials or supplies were not disinfected prior to entering the aseptic processing areas.
Specifically,
During lhe <Redacted B4> of Atropine eye drops lot 02122020@8 in ISO 5 Laminar Airflow Hood <Redacted B4> 02/12/2020, the syringe tip caps, needle packages, and dropper bottle packaging were not disinfected prior to entering into the ISO 5 classified laminar air flow hood from the ISO 7 classified clean room shelving and cabinets. Original cardboard outer packaging is also stored in the ISO 7 areas.
Observation 5
Personnel engaged in aseptic processing were observed with exposed hair.
Specifically,
During the <Redacted B4> of atropine eye drops lot 02122020@8 in ISO 5 Laminar Airflow Hood on 02/12/2020, the pharmacist was observed with exposed hair while working in the 1S0 5 laminar airflow hood stationed within the ISO 7 cleanroom.
Observation 6
The <Redacted B4> intended to render final product sterile was not pharmaceutical grade.
Specifically,
The pharmacist stated the <Redacted B4> (product code <Redacted B4>) is used to produce oil based sterile drug products such as Testosterone Cyp [M injection and Hydroxyprogesterone IM injection. The <Redacted B4> states its use as "<Redacted B4>" It does not indicate that it is pharmaceutical grade. Drugs produced using this <Redacted B4> include but are not limited to:
• Hydroxyprogesterone Caproate 350 mg/mL Injection lot 01 I 62020@56
• Testosterone Cypionate 200 MS prescription <Redacted B4>
Observation 7
You used a non-pharmaceutical grade component in the formulation of a drug product.
Specifically,
1. Food grade <Redacted B4> was used for the production of Progesterone Vaginal Suppository Capsules lot 01102020@5
2. Food grade <Redacted B4> was used for Eugenol topical dental cream lot 01232020@28.
Observation 8
Environmental monitoring was inadequately performed in your aseptic processing areas.
Specifically,
The pharmacist stated that sampling for microbial contamination analysis is collected on personnel fingertips and ISO 5 surface areas after sanitation and cleaning of the areas with sterile <Redacted B4> spray on sterile wipes. This method does not allow for adequate product evaluation to determine if microbial contamination was present during aseptic production.
Observation 9
Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations
Specifically,
Media fills conducted on 01/08/2019, • 07/08/2019, and 11/25/2019 are performed using operations consisting of drawing up syringes to produce <Redacted B4> mL vials via <Redacted B4>. Your worst-case activity and most challenging operation includes <Redacted B4> into batch sizes as large as <Redacted B4> units of <Redacted B4> mL vial stock solutions which are then further processed into intrathecal syringes. In addicion, media fills do not reflect the normal pharmacist operations observed in the ISO 5 aseptic processing hoods in which the pharmacists move themselves and materials over 6 times between the ISO 5 aseptic processing hoods and the ISO 7 environment.
Observation 10
You produced hazardous drugs without providing adequate cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.
Specifically,
The <Redacted B4> brand ~ are used interchangeably for production of non-sterile hazardous drugs and non-hazardous drugs. The <Redacted B4> are not identified and are moved between the hazardous negative pressure room, the buffer room, and the unclassified non-sterile production hallway <Redacted B4> are cleaned with <Redacted B4> solution with no assurance that the cleaning solution acts as a deactivating agent. The pharmacist stated the following non-sterile drugs were produced using the <Redacted B4>
- Progesterone 160 mg/gm phytobase, (hazardous) lot 02032020@68 on 02/03/2020 using an unidentified <Redacted B4> 4) (15) (4)
- Nitroglycerin 0.15% Ointment, (non-hazardous) lot 02062020@27 on 02/06/2020 using an unidentified <Redacted B4> (4) (6)(4)
Inspection Oct 2, 2017 to Dec 18, 2017: 6 observations
- Firm on the cover
- Innovative Intrathecal Solutions, Inc. dba Innovative Compounding Pharmacy, 41538 Eastman Dr, Suite A, 21P CODE, COUNTRY Murrieta, CA 92562-8007
- FEI number
- 3013556857
- Establishment type on the cover
- Producer of Human and Veterinary Drug Products
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-2445
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
Specifically, your firm's media fill studies are used to support all sterile produced drug products. The media fill studies performed on 1/7/2017 and 6/30/2017 by all three pharmacists who handle the sterile drug product preparations <Redacted B4> an <Redacted B4> were deficient in that:
A. The media lots used in the studies were not demonstrated to support the microbial growth through growth promotion test.
B. There were no control samples documented in the media fill reports. The use of control samples is required by your firm's media fill procedure.
C. There were no records showing the quantities of media used in the media fill studies.
D. There were no records of <Redacted B4> used in the media fill studies.
E. There were no records indicating that the <Redacted B4> was evaluated.
F. No environmental and personnel monitoring were carried out at the time media fill studies were performed on 6/30/2017.
G. The incubator used for the media samples was not qualified.
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Specifically,
fH•I l A. Your firm's <Redacted B4> after each lot of sterile drug product preparation is not adequate in that the test result is subjectively assessed by your pharmacist <Redacted B4> the <Redacted B4> through <Redacted B4> during <Redacted B4> to evaluate the <Redacted B4> of the <Redacted B4> rather than a quantiative measurement. There is no specification for this assessment.
B. On 12/5/2017 during the preparation of Methylcobalamin Injection lot I 2052017@16 by pharmacist <Redacted B4> a non-sterile wipe was observed to be used inside the ISO 5 LFH to clean the ISO 5 bench, walls, and the exterior of container closures including the vial stopper surface that was punctured to introduce sterile drug product into the vial.
Per your PI C's estimate, your firm prepares on average about •( sterile drug product units a day.
Observation 3
Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.
Specifically, the following gowning materials used during the preparation of sterile drug products are not of sterile grade: hair bonnet, mask, lab coat, and shoe cover. ln the past 3 monthsf•( lots of the sterile Omnipaque Injection office stock were produced.
Observation 4
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically, your firm does not perform environmental monitoring when sterile drug products are prepared. In addition, personnel monitoring is not carried out after sterile drug preparations. In the past 3 months, <Redacted B4> ( lots of the sterile Omnipaque Injection office stock were produced.
Observation 5
Results of stability testing are not used in determining appropriate storage conditions and expiration dates.
Specifically, the I80 days of beyond use date (BUD) for the Omnipaque Injection product prepared by your firm was not supported by stability data.
Observation 6
Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
Specifically, not all batches of sterile drug products prepared by your firm were tested for sterility and/or endotoxin before release. For example,
Your firm prepared Omnipaque Injection sterile drug product for doctor office stock by using commercially purchased sterile product to repackage it to smaller volume throught <Redacted B4> However, no sterility and/or endotoxin tests were performed on each batch before release. For example,
A. Omnipaque 300 mg/mL Injection product lot 10042017@44 <Redacted B4> units of 10 mL vial distributed) and lot 11282017@34 <Redacted B4> units of 3 mL vial distributed) were not tested for sterility and endotoxin.
B. Omnipaque 300 mg/mL Injection product lot 10132017@4 <Redacted B4> units of 6 mL vial distributed) and lot 11032017@40 <Redacted B4> units of 10 mL vial distributed) were only tested for sterility, but not endotoxin.
State board of pharmacy records
The California State Board of Pharmacy file dated Nov 6, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status |
|---|---|---|---|---|
| PHY 49935 | Retail Pharmacy | Innovative Compounding Pharmacy | Murrieta | Active |
What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.
Close but not exact board records
These board records share a name with this pharmacy but did not meet this index’s matching rule (same name, same city, same state), so they are not treated as its license. They may belong to a separate business.
- License LSC 99600, Innovative Compounding Pharmacy, Folsom, status Active: same name and state, different city.
- License PHY 48417, Innovative Compounding Pharmacy, Folsom, status Active: same name and state, different city.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- California State Board of Pharmacy license file
- California State Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.